Table 2.

Studies investigating the relationship of fetuin-A with CVD in subjects with and without NAFLD.

Author (Reference)	Study Population	Study Design	CVD Risk Assessment	Association of Fetuin-A with CVD Risk
Jensen et al. [62]	3810 older subjects	Prospective	CVD event or CVD death	Negative
Laughlin et al. [63]	1688 women	Prospective	CVD event or CVD death	Negative
Sun et al. [64]	466 patients with IS	Prospective	IS	None
Caglar et al. [65]	198 nondiabetic patients with CKD	Retrospective	FMD and cIMT	Positive
Zhao et al. [75]	241 patients with T2D	Retrospective	Coronary angiography	Positive
Weikert et al. [67]	227 patients with MI and 168 patients with IS	Prospective	MI or IS	Positive
Vörös et al. [68]	171 patients with CVD and 81 controls	Cross-sectional	Biomarkers of ED	Positive
Mori et al. [70]	141 healthy subjects	Cross-sectional	Carotid arterial stiffness	Positive
Sato et al. [44]	295 subjects with NAFLD	Cross-sectional	cIMT	Negative
Dogru et al. [72]	115 subjects with NAFLD	Cross-sectional	Biomarkers of ED and cIMT	Positive
Ballestri et al. [73]	70 subjects with and without CVD	Cross-sectional	Coronary angiography	Negative
Nascimbeni et al. [74]	45 patients with CVD and 104 patients with PAD	Cross-sectional	CAD PAD	Positive

NAFLD: nonalcoholic fatty liver disease, CVD: cardiovascular disease, IS: ischemic stroke, CKD: chronic kidney disease, FMD: flow mediated dilation, cIMT: carotid intima–media thickness, T2D: type 2 diabetes, MI: myocardial infarction, ED: endothelial dysfunction, PAD: peripheral artery disease, CAD: coronary artery disease.